These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2559738)

  • 61. Inhibition of the myocardial Ca(2+)-current (ICa) by the enantiomers of DPI 201-106 and BDF 8784.
    Ravens U; Pfeifer T; Wettwer E; Grundke M
    Br J Pharmacol; 1991 Oct; 104(2):490-4. PubMed ID: 1665740
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure.
    Kieback AG; Iven H; Stolzenburg K; Baumann G
    J Cardiovasc Pharmacol; 1998 Oct; 32(4):629-36. PubMed ID: 9781932
    [TBL] [Abstract][Full Text] [Related]  

  • 63. In vitro pharmacological properties of a series of isoprenaline derivatives.
    Eigenmann R; Burkard WP; Holck M; Märki HP; Osterrieder W; Goodman M; Melmon KL
    Arzneimittelforschung; 1989 Aug; 39(8):842-7. PubMed ID: 2554933
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Characterization of positive inotropic effect of endothelin on mammalian ventricular myocardium.
    Takanashi M; Endoh M
    Am J Physiol; 1991 Sep; 261(3 Pt 2):H611-9. PubMed ID: 1653535
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacological actions of APP 201-533, a novel cardiotonic agent.
    Salzmann R; Bormann G; Herzig JW; Markstein R; Scholtysik G
    J Cardiovasc Pharmacol; 1985; 7(3):588-96. PubMed ID: 2410694
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility.
    Weishaar RE; Kobylarz-Singer DC; Steffen RP; Kaplan HR
    Circ Res; 1987 Oct; 61(4):539-47. PubMed ID: 2820608
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phosphodiesterase inhibition and Ca2+ sensitization.
    Ravens U; Himmel HM; Flüss M; Davia K; Harding SE
    Mol Cell Biochem; 1996 Apr 12-26; 157(1-2):245-9. PubMed ID: 8739254
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Determination of saterinone enantiomers in plasma samples with an internal standard using a Chiralcel OD column, fractionation and reversed-phase chromatography.
    Rudolph M; Volk D; Schmiedel G
    J Chromatogr; 1990 Dec; 535(1-2):263-9. PubMed ID: 2089055
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Imidazo[1,2-a]pyridines. I. Synthesis and inotropic activity of new 5-imidazo[1,2-a]pyridinyl-2(1H)-pyridinone derivatives.
    Yamanaka M; Miyake K; Suda S; Ohhara H; Ogawa T
    Chem Pharm Bull (Tokyo); 1991 Jun; 39(6):1556-67. PubMed ID: 1934178
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lack of functional influence by prenalterol through alpha 1-adrenoceptors in rat myocardium.
    Aass H; Hedberg A; Skomedal T; Carlsson E; Osnes JB
    Acta Pharmacol Toxicol (Copenh); 1983 Jul; 53(1):12-5. PubMed ID: 6310957
    [TBL] [Abstract][Full Text] [Related]  

  • 71. (Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase.
    Lampe JW; Chou YL; Hanna RG; Di Meo SV; Erhardt PW; Hagedorn AA; Ingebretsen WR; Cantor E
    J Med Chem; 1993 Apr; 36(8):1041-7. PubMed ID: 8386770
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The effects of the stereoisomers of propafenone and diprafenone in guinea-pig heart.
    Groschner K; Lindner W; Schnedl H; Kukovetz WR
    Br J Pharmacol; 1991 Mar; 102(3):669-74. PubMed ID: 1364837
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Synthesis and pharmacological characterization of functionalized 2-pyridones structurally related to the cardiotonic agent milrinone.
    Fossa P; Menozzi G; Dorigo P; Floreani M; Mosti L
    Bioorg Med Chem; 2003 Nov; 11(22):4749-59. PubMed ID: 14556790
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Calcium sensitization as a positive inotropic mechanism in diseased rat and human heart.
    Nankervis R; Lues I; Brown L
    J Cardiovasc Pharmacol; 1994 Oct; 24(4):612-7. PubMed ID: 7528844
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Differential effects of BDF 9148 and DPI 201-106 on action potential and contractility in rat and guinea pig myocardium.
    Hoey A; Amos GJ; Wettwer E; Ravens U
    J Cardiovasc Pharmacol; 1994 Jun; 23(6):907-15. PubMed ID: 7523782
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.
    von der Leyen H
    Klin Wochenschr; 1989 Jun; 67(12):605-15. PubMed ID: 2671473
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cardiovascular actions of DPI 201-106, a novel cardiotonic agent.
    Salzmann R; Scholtysik G; Clark B; Berthold R
    J Cardiovasc Pharmacol; 1986; 8(5):1035-43. PubMed ID: 2429077
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
    Sircar I; Haleen SJ; Burke SE; Barth H
    J Med Chem; 1992 Nov; 35(23):4442-9. PubMed ID: 1447743
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A method to assess concomitant cardiac phosphodiesterase inhibition and positive inotropy.
    Kenakin TP; Scott DL
    J Cardiovasc Pharmacol; 1987 Dec; 10(6):658-66. PubMed ID: 2450236
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Interaction of enantiomers of hydroxy tolazoline with adrenoceptors.
    Sengupta JN; Hamada A; Miller DD; Patil PN
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Apr; 335(4):391-6. PubMed ID: 3600818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.